Dan W. Reynolds, PhD
Dan W. Reynolds, PhD, is a research investigator II in the chemical development analytical sciences department at GlaxoSmithKline, Five Moor Dr., PO Box 13398, Research Triangle Park, NC 27709.
Articles
Available Guidance and Best Practices for Conducting Forced Degradation Studies
Dan W. Reynolds, PhD;Karen M. Alsante, PhD;Kevin L. Facchine, PhD;June F. Mullaney, PhD;Michael G. Motto, PhD;Todd D. Hatajik
February 1st 2002Participants at a Pharmaceutical Research and Manufacturers of America workshop share their views about the acceptable analytical practices of conducting forced degradation studies.
Latest Updated Articles
Published: October 11th 2024 | Updated: October 18th 2024
Buy, Sell, Hold: Cell and Gene Therapy - Part 1
Published: September 10th 2024 | Updated: September 18th 2024
CPHI Milan Announces 2024 CPHI Pharma Award Finalists
Published: February 23rd 2024 | Updated: December 22nd 2024
Europa Perspectives: Helping to Navigate the Regulatory System
Published: December 13th 2024 | Updated: December 22nd 2024
FDA Creates CDER Center for Real-World Evidence Innovation
Published: December 5th 2024 | Updated: December 22nd 2024
Leveraging Advancements in Bioanalytical Testing
Published: December 7th 2024 | Updated: December 22nd 2024
Exploring Opportunities for LNP Delivery in mRNA
